MedTrace Logo

Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis

NCT03761628 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-07-25

Study results available
· View outcomes & findings →

Summary

This is an open-label, single-armed, multi-center study to evaluate clinical performance, tolerability, and safety of Gedea Pessary in 24 adult women with vulvovaginal candidias (VVC). On Day 0, patients will have gynecological examination, vaginal samples taken, and will receive the investigational product to be self-administered. Patients will be examined after 7 days with respect to VVC signs and symptoms and if not cured, will receive prolonged treatment for one additional week. Patients will be followed-up by telephone up to 29 days after last treatment. Vaginal samples will be used for confirming diagnosis and microbiome analyzes. Patient questionnaires will be used for assessing VVC symptoms, usability, and adverse events (AEs).

Conditions

  • Vulvovaginal Candidiasis

Interventions

DEVICE

pHyph generation I

A vaginal tablet for the treatment of VVC to be administered every 48 hours

Sponsors & Collaborators

  • Gedea Biotech AB

    lead INDUSTRY

Principal Investigators

  • Monika Cardell, MD, PhD · Kvinnokliniken, Region Skåne

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-07
Primary Completion
2019-12-16
Completion
2020-01-15

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03761628 on ClinicalTrials.gov